Stereotaxis (NYSE:STXS) and Abbott (NYSE:ABT) agreed to a global collaboration to integrate Abbott’s EnSite X EP System with its Robotic Magnetic Navigation systems. The combination brings together highly detailed real...
Stereotaxis (NYSE: STXS) will be added to the Russell 2000 and Russell 3000 indexes after the close on June 26, as part of the Russell indexes annual reconstitution. “This is another step forward in our effort to...
Cowen launched coverage of Stereotaxis (NYSE American:STXS) with an “outperform” rating and $6 price target. The stock closed at $2.71 on April 8. Genesis is Stereotaxis’ next-generation robotic magnetic navigation...
Stereotaxis (NYSE:STXS) received FDA 510(k) clearance of the Genesis RMN System for the robotic navigation of magnetic ablation catheters to treat heart rhythm disorders. “Genesis is a leap forward in robotic magnetic...
Kimberly Peery Stereotaxis (NYSE American:STXS) appointed Kimberly Peery as CFO, effective October 1, replacing Martin Stammer, who has accepted a position as CFO of a large professional services firm in the St. Louis...
The common shares of Stereotaxis (OTCQX:STXS) were approved for listing on the NYSE American exchange, effective with the opening on Sept. 6, with the same stock symbol. They will trade on the OTCQX until the close on...
Stereotaxis (NASDAQ:STXS) announced that the Montreal Heart Institute (MHI) is now performing ablation procedures using its newly installed Niobe ES and the Vdrive robotic systems. MHI is the first hospital in...
By Len Zehr After receiving regulatory clearance in Japan of its Niobe Remote Magnetic Navigation system for cardiac ablations last March, Stereotaxis (NASDAQ:STXS) now expects to achieve reimbursement approval by the...